XNASCSTL
Market cap751mUSD
Dec 27, Last price
26.83USD
1D
-1.00%
1Q
-3.70%
IPO
16.70%
Name
Castle Biosciences Inc
Chart & Performance
P/E
—
P/S
3.42
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
20.27%
Rev. gr., 5y
57.35%
Revenues
220m
+60.38%
Net income
-57m
L-14.41%
CFO
-6m
L-86.49%
Earnings
Feb 26, 2025
Profile
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 219,788 60.38% | 137,039 45.65% | 94,085 50.18% | ||||
Cost of revenue | 278,752 | 219,915 | 45,468 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (58,964) | (82,876) | 48,617 | ||||
NOPBT Margin | 51.67% | ||||||
Operating Taxes | 101 | (1,766) | (8,720) | ||||
Tax Rate | |||||||
NOPAT | (59,065) | (81,110) | 57,337 | ||||
Net income | (57,466) -14.41% | (67,138) 114.55% | (31,292) 204.28% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | (4,865) | (855) | 3,117 | ||||
BB yield | 0.84% | 0.14% | -0.29% | ||||
| Debt | |||||||
Debt current | 2,274 | 1,777 | 1,179 | ||||
Long-term debt | 29,533 | 24,843 | 14,979 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 90 | 18,411 | |||||
Net debt | (211,292) | (233,092) | (314,783) | ||||
| Cash flow | |||||||
Cash from operating activities | (5,626) | (41,655) | (18,983) | ||||
CAPEX | (13,621) | (5,632) | (3,483) | ||||
Cash from investing activities | (16,183) | (166,545) | (66,657) | ||||
Cash from financing activities | (2,298) | 1,515 | 5,421 | ||||
FCF | (77,451) | (90,319) | 47,152 | ||||
| Balance | |||||||
Cash | 243,099 | 258,625 | 329,633 | ||||
Long term investments | 1,087 | 1,308 | |||||
Excess cash | 232,110 | 252,860 | 326,237 | ||||
Stockholders' equity | (218,208) | (161,259) | (93,742) | ||||
Invested Capital | 625,949 | 573,772 | 531,277 | ||||
ROIC | 11.33% | ||||||
ROCE | 11.10% | ||||||
| EV | |||||||
Common stock shares outstanding | 26,802 | 26,054 | 25,137 | ||||
Price | 21.58 -8.33% | 23.54 -45.09% | 42.87 -36.16% | ||||
Market cap | 578,387 -5.69% | 613,311 -43.09% | 1,077,623 -15.22% | ||||
EV | 367,095 | 380,219 | 762,840 | ||||
EBITDA | (46,634) | (72,333) | 52,024 | ||||
EV/EBITDA | 14.66 | ||||||
Interest | 11 | 17 | 1,000 | ||||
Interest/NOPBT | 0.00% | ||||||